Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

Phase 4

Completed

• Conditions: House Dust Mite Allergy

• Registration Number: NCT00263549
• Lead Sponsor: Allergopharma GmbH & Co. KG

Brief Summary

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Detailed Description

Not available

Study Timeline

• Study Start: 2002-09
• Primary Completion: 2005-02
• Study First Submitted: 2005-12-08
• Study First Submitted QC: 2005-12-08
• Study First Posted: 2005-12-09
• Study Completion: 2006-02
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-08
• Last Update Posted: 2013-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Positive skin prick test to house dust mite,
• Positive RAST test to house dust mite,
• Positive provocation test result to house dust mite,

Exclusion Criteria

• Serious chronic diseases,
• Other perennial allergies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Allergopharma GmbH & Co. KG; 🇩🇪 Reinbek, Germany